Infliximab
- Generic Name
- Infliximab
- Brand Names
- Avsola, Flixabi, Inflectra, Remicade, Renflexis, Zessly, Remsima
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 170277-31-3
- Unique Ingredient Identifier
- B72HH48FLU
- Background
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions . Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammato...
- Indication
用于治疗：
⑴类风湿性关节炎：本品常与甲氨蝶呤合用于中重度活动性类风湿性关节炎；
⑵克罗恩病及瘘管性克罗恩病；
⑶强直性脊柱炎等自身免疫性疾病，以减轻症状和体征，改善身体机能，预防患者残疾。
⑷用于银屑病关节炎的治疗【美国FDA已批准；英国风湿病学会/英国风湿病卫生专业人员协会《BSR／BHPR—应用生物制剂治疗银屑病关节炎指南》2012版；欧洲抗风湿病联盟《EULAR—银屑病关节炎药 物治疗管理建议》2011版
】。
⑸用于6岁及以上儿童溃疡性结肠炎的治疗【美国FDA已批准；中华医学会内科学会《炎症性肠病诊断与治疗的共识意见》；中华医学会消化病学分会炎症性肠病学组《英夫利西治疗克罗恩病的推荐方案（2011年】。
- Associated Conditions
- Ankylosing Spondylitis (AS), Chronic Plaque Psoriasis, Fistulizing Crohn's Disease, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Rheumatoid Arthritis, Moderately to Severely Active Ulcerative Colitis, Pediatric Crohn’s Disease, Psoriatic Arthritis
- Associated Therapies
- -
An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2012-10-18
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT00207714
A Study of Infliximab (Remicade) in Patients With Ankylosing Spondylitis.
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 279
- Registration Number
- NCT00207701
Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2015-06-10
- Target Recruit Count
- 19
- Registration Number
- NCT00201799
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Islet Transplantation Using Campath-1H and Infliximab Induction
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-10-02
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 12
- Registration Number
- NCT00175266
- Locations
- 🇨🇦
University of Alberta - Clinical Islet Transplant Program, Edmonton, Alberta, Canada
TNFalfa Blocking Treatment of Spondylarthropathies
- Conditions
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2007-04-10
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT00133315
- Locations
- 🇩🇰
Hvidovre University Hospital, Hvidovre, Denmark
🇩🇰Vejle Sygehus, Vejle, Denmark
🇩🇰Bispebjerg Hospital, Copenhagen, Denmark
Beryllium Infliximab Study: Clinical Interventional Trial
- First Posted Date
- 2005-05-27
- Last Posted Date
- 2016-06-02
- Lead Sponsor
- Maier, Lisa, M.D.
- Target Recruit Count
- 13
- Registration Number
- NCT00111917
- Locations
- 🇺🇸
National Jewish Health, Denver, Colorado, United States
A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis
- Conditions
- First Posted Date
- 2005-04-01
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 378
- Registration Number
- NCT00106834
A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis
- Conditions
- First Posted Date
- 2005-04-01
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 683
- Registration Number
- NCT00106847
A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Ulcerative Colitis
- Conditions
- First Posted Date
- 2004-11-15
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 364
- Registration Number
- NCT00096655
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis
- Conditions
- First Posted Date
- 2004-02-04
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT00076726
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.